-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Post-antibiotic era is a worldwide challenge for health care: what to do ?
Asad U Khan
Letter to Editor: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
Review: Clinical Trail Outcomes: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
Core outcomes in vitiligo trials: progress and challenges
V Eleftheriadou, KS Thomas, JM Batchelor, JC Ravenscroft, ME Whitton
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
US FDA approves trastuzumab for the treatment of HER2-positive metastatic stomach cancer
News and Views: Clinical Investigation
-
US FDA approves trastuzumab for the treatment of HER2-positive metastatic stomach cancer
News and Views: Clinical Investigation
-
US FDA approves trastuzumab for the treatment of HER2-positive metastatic stomach cancer
News and Views: Clinical Investigation
-
US FDA approves trastuzumab for the treatment of HER2-positive metastatic stomach cancer
News and Views: Clinical Investigation
-
US FDA approves trastuzumab for the treatment of HER2-positive metastatic stomach cancer
News and Views: Clinical Investigation
-
US FDA approves trastuzumab for the treatment of HER2-positive metastatic stomach cancer
News and Views: Clinical Investigation